Skip to main content
Figure 4 | Retrovirology

Figure 4

From: Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection

Figure 4

Association of expression of MHC class I allele Mamu-A*01 with viremia and early virologic response to tenofovir therapy. (A) No significant difference was detected between the 3 Mamu-A*01-positive and the 9 Mamu-A*01-negative animals with regard to viremia during the first 20 weeks of infection (two-way ANOVA, p = 0.86) or virus levels at the start of tenofovir treatment (vertical dotted line; two-tailed t-test: p = 0.29). However, during the first 4 weeks following the start of tenofovir treatment (dashed-line box), Mamu-A*01-positive animals had a bigger reduction in viral RNA levels than Mamu-A*01-negative animals (two-way ANOVA, p = 0.02); there was no association of the Mamu-B*01 allele with viremia (data not shown). (B) Comparison of disease-free survival following tenofovir treatment revealed no significant difference between the 3 Mamu-A*01-positive and 9 negative animals (logrank test, p = 0.14).

Back to article page